Additional Contamination Identified in NECC Products

December 4, 2012

The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) have identified additional microbial contamination in medical products from the New England Compounding Center (NECC), according to a CDC Health Alert.

As part of the ongoing investigation of the multistate outbreak of fungal meningitis, CDC and FDA have identified additional microbial contamination in unopened vials of betamethasone, cardioplegia and triamcinolone solutions distributed and recalled from NECC.

To date, although CDC has received reports of illness in patients who have received these medications, including some patients who had evidence of meningeal inflammation, CDC and public health officials have no reports of laboratory-confirmed bacterial or fungal meningitis, spinal, or paraspinal infections caused by these products.

CDC continues to recommend that clinicians remain alert for the possibility that infections may have resulted from injection of NECC products, and that routine laboratory and microbiologic tests, including bacterial and fungal cultures, should be obtained as deemed necessary by treating clinicians.

Clinicians should continue to report infections potentially related to NECC products to FDA's MedWatch and to state health departments.

Click here to read the full CDC Health Alert.